IGF-1 (Mecasermin)

Mechanism of Action

IGF-1 (mecasermin) is a recombinant human insulin-like growth factor-1 that works by mimicking the natural IGF-1 hormone's cellular and physiological effects. The available evidence provides limited direct mechanistic detail, but several key pathways can be identified from clinical studies.

Growth and Development Pathway
IGF-1 functions as a critical mediator of growth hormone effects, promoting cellular growth and development. Clinical data from the IGFD Registry demonstrates that recombinant IGF-1 (rhIGF-1) treatment can improve height outcomes in patients with severe growth failure, indicating its effectiveness in stimulating linear growth through activation of IGF-1 receptors in target tissues.

Metabolic Effects
One completed clinical trial (NCT01588093) specifically examined "IGF-I Induced Muscle Glucose Uptake," suggesting that IGF-1 enhances glucose metabolism in muscle tissue. This metabolic effect may contribute to its therapeutic benefits but also explains the observed risk of hypoglycemia as a side effect. Registry data indicates that hypoglycemia occurs with predictable frequency in patients receiving rhIGF-1, reflecting the compound's insulin-like metabolic activities.

Neurological Applications
The mechanism in neurological conditions appears related to IGF-1's role in neuronal development and synaptic function. Multiple clinical trials have investigated mecasermin for Rett syndrome (NCT01777542) and 22q13 deletion syndrome (NCT01525901), both neurodevelopmental disorders. A 2024 review suggested IGF-1 has potential as both a diagnostic tool and treatment target for autism spectrum disorders, though the specific neurological mechanisms require further clarification.

Tissue Repair and Protection
Clinical trials have explored IGF-1's potential in cardiac tissue repair following myocardial infarction (NCT01438086) and prevention of bronchopulmonary dysplasia in premature infants (NCT03253263), suggesting broader tissue-protective or regenerative mechanisms beyond growth promotion.

Evidence Limitations
While the clinical applications are diverse, the available evidence provides limited detailed mechanistic data at the molecular level. The therapeutic effects appear to result from IGF-1's fundamental roles in growth signaling, metabolic regulation, and possibly neuroprotection, but more mechanistic research would be needed to fully characterize the pathways involved in each clinical application.

This information is for educational purposes only and should not be considered personalized medical advice. Consult healthcare providers for treatment decisions.

Mecasermin (recombinant human IGF-1) has several established and investigational clinical applications, with the strongest evidence supporting its use in growth disorders and emerging research in neurological conditions.

Primary Growth Hormone Insensitivity Syndrome (GHIS)

The most established clinical application for mecasermin is treating severe primary IGF-1 deficiency, particularly in patients with growth hormone insensitivity syndrome. Real-world data from the IGFD Registry demonstrates that patients treated with recombinant IGF-1 can achieve meaningful improvements in near-adult height outcomes. Clinical characteristics studies show treatment efficacy in patients with primary severe IGF-1 deficiency, though specific height gains and response rates require further detailed analysis from the registry data.

Safety Considerations

A significant clinical concern with mecasermin therapy is hypoglycemia risk. Data from the European IGFD Registry identifies frequency and predictive factors for hypoglycemia in patients receiving recombinant IGF-1 treatment. This adverse effect requires careful monitoring and patient selection, particularly important given the pediatric population typically receiving this therapy.

Investigational Neurological Applications

Several clinical trials have explored mecasermin's potential in neurological conditions:

Rett Syndrome: A completed Phase 2 trial (NCT01777542) investigated recombinant IGF-1 for Rett syndrome treatment. A systematic review examined mecasermin's efficacy in this condition, though trofinetide has emerged as a more established treatment option for Rett syndrome.

Phelan-McDermid Syndrome: A completed Phase 2 trial (NCT01525901) evaluated mecasermin in 22q13 deletion syndrome, representing research into rare genetic neurodevelopmental disorders.

Autism Spectrum Disorders: Research suggests IGF-1 may have potential as both a diagnostic biomarker and treatment target for autism spectrum disorders, though this remains investigational.

Other Investigational Uses

Clinical trials have explored mecasermin in several other conditions:

• Cardiovascular applications: A completed Phase 1/2 trial examined IGF-1's safety and efficacy in heart attack patients
• Retinopathy of prematurity: Cochrane systematic review evidence exists for IGF-1 in preventing or treating this condition in premature infants
• Bronchopulmonary dysplasia: An ongoing Phase 2 trial is recruiting extremely premature infants for BPD prevention

Biomarker Applications

Beyond therapeutic use, IGF-1 serves as a clinical biomarker in certain conditions. In hemophilic arthropathy, IGF-1 levels correlate with clinical and ultrasound scores alongside other biomarkers, potentially informing disease monitoring strategies.

Clinical Note: The evidence base varies significantly across these applications. While growth hormone insensitivity syndrome represents established clinical use with registry data, many neurological and other applications remain investigational with limited clinical trial evidence. Patients should consult with appropriate specialists regarding specific treatment decisions.

Safety Profile of IGF-1 (Mecasermin)

Known Side Effects

Hypoglycemia appears to be the most significant and well-documented adverse effect of mecasermin treatment. Data from the EU-IGFD Registry specifically examined the frequency and predictive factors of hypoglycemia in patients treated with recombinant human IGF-1, indicating this is a recognized and monitored safety concern requiring clinical attention.

Evidence limitations: While hypoglycemia is clearly documented as a concern, the provided evidence does not include comprehensive details about the full spectrum of other potential side effects, their frequencies, or severity profiles. Additional safety data would be needed for a complete assessment.

Contraindications and Precautions

The evidence provided does not contain specific information about absolute contraindications for mecasermin use. However, given the documented risk of hypoglycemia, careful monitoring would be essential in patients with diabetes or other conditions affecting glucose metabolism.

Drug Interactions

Evidence gap: The provided research does not include information about drug interactions with mecasermin. This represents a significant knowledge gap that would require additional clinical data to address properly.

Special Populations

Based on the available evidence, mecasermin has been studied in several specific populations:

• Pediatric patients with severe IGF-1 deficiency and growth failure
• Patients with Rett syndrome (though one study notes that trofinetide, not mecasermin, is described as "a pioneering treatment" for this condition)
• Premature infants (being investigated for bronchopulmonary dysplasia prevention)
• Patients with 22q13 deletion syndrome (Phelan-McDermid syndrome)

Evidence limitations: The safety profiles specific to these populations are not detailed in the provided abstracts. Additionally, safety data for pregnant or breastfeeding women, elderly patients, and those with hepatic or renal impairment are not available in the current evidence.

Clinical Monitoring Requirements

Given the documented hypoglycemia risk, blood glucose monitoring would be essential during mecasermin treatment, though specific monitoring protocols are not detailed in the available evidence.

---

This safety information is based on limited research abstracts and clinical trial listings. A complete safety assessment would require access to full study reports, prescribing information, and regulatory documentation. Patients should consult healthcare providers for comprehensive safety information and individualized risk assessment.

Research Papers and Clinical Trials

The research on IGF-1 (mecasermin) spans several therapeutic areas, with studies examining both established and experimental uses of this recombinant growth factor.

Growth Disorders and IGF-1 Deficiency

A 2026 study published in The Journal of Clinical Endocrinology and Metabolism examined real-world data from the IGFD Registry on near-adult height outcomes in patients treated with recombinant human IGF-1 for severe growth failure. A separate 2024 study in Frontiers in Pediatrics analyzed clinical characteristics and treatment efficacy in patients with primary severe IGF-1 deficiency receiving recombinant IGF-1 therapy. These studies provide evidence for the established use of mecasermin in growth hormone insensitivity syndromes.

Safety data comes from a 2023 analysis in The Journal of Clinical Endocrinology and Metabolism that examined hypoglycemia frequency and predictive factors in patients treated with recombinant human IGF-1, using data from the EU-IGFD Registry.

Neurological Applications

A systematic review published in Neurogenetics in 2025 examined mecasermin for treating Rett Syndrome, while a 2024 review in Cureus explored IGF-1's potential as both a diagnostic tool and treatment target for autism spectrum disorders. These reviews suggest expanding interest in IGF-1 for neurodevelopmental conditions, though the evidence base appears limited.

Clinical Trials

Several completed clinical trials have investigated IGF-1 in diverse conditions. A Phase 1/2 trial (NCT01438086) evaluated safety and efficacy in heart attack patients. A Phase 2 study (NCT01525901) examined IGF-1 in 22q13 deletion syndrome (Phelan-McDermid Syndrome), and another Phase 2 trial (NCT01777542) investigated recombinant human IGF-1 for Rett Syndrome treatment.

Other Applications

A 2026 Cochrane systematic review examined IGF-1 for preventing or treating retinopathy of prematurity. Additionally, research has explored IGF-1 as a biomarker, with a 2026 cross-sectional study in Rheumatology International finding associations between IGF-1 and clinical scores in hemophilic arthropathy.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for guidance on specific medical conditions and treatments.

Protocols

Based on published literature, mecasermin (recombinant human IGF-1) dosing protocols vary significantly depending on the indication and patient population studied.

Primary IGF-1 Deficiency (Approved Indication)

The most established protocols are for severe primary IGF-1 deficiency, where mecasermin is FDA-approved:

• Starting dose: Typically 0.04-0.08 mg/kg administered subcutaneously twice daily
• Dose escalation: Gradual increases based on tolerance and response, up to maximum of 0.12 mg/kg twice daily
• Administration: Given shortly before or after meals to minimize hypoglycemia risk
• Monitoring: Regular assessment for hypoglycemia, especially during dose initiation and escalation

Investigational Uses

Limited data exists for other conditions studied in clinical trials:

Rett Syndrome: Phase 2 studies have examined various dosing regimens, though specific protocols from the available evidence are not detailed enough to report precise dosing ranges.

Cardiac Applications: Phase 1/2 trials have investigated IGF-1 in post-myocardial infarction patients, but dosing protocols are not clearly established in the available literature.

Premature Infants: Studies examining bronchopulmonary dysplasia prevention have used investigational formulations, but standard protocols are not yet established.

Safety Considerations

Available evidence emphasizes several important monitoring requirements:

• Hypoglycemia monitoring: This appears to be the most significant adverse effect requiring regular blood glucose monitoring
• Growth parameter tracking: Regular measurement of growth velocity and bone age
• Injection site assessment: Monitoring for lipohypertrophy at injection sites

Evidence Limitations

The available literature provides limited specific dosing details for many investigational uses. Most detailed protocols are available only for the approved indication of severe primary IGF-1 deficiency. For other conditions, protocols remain investigational and are not standardized.

---

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Mecasermin dosing and administration should only be determined by qualified healthcare providers based on individual patient assessment, approved prescribing information, and current clinical guidelines.

Outcomes

The outcomes evidence for IGF-1 (Mecasermin) spans several therapeutic areas, with the strongest data in growth disorders and emerging evidence in neurological conditions.

Growth Disorders

Real-world registry data demonstrates measurable height improvements in patients with severe growth failure. Patients with primary severe IGF-1 deficiency treated with recombinant IGF-1 show treatment efficacy, though specific outcome measures are not detailed in the available evidence. Near-adult height outcomes have been documented in the IGFD Registry, indicating sustained growth benefits, but quantitative results are not provided in these abstracts.

Safety Profile

Hypoglycemia represents a notable safety concern, with registry data identifying frequency rates and predictive factors for this adverse event in patients receiving rhIGF-1. The evidence indicates this is a monitored and characterized risk, though specific incidence rates are not available from the provided abstracts.

Neurological Applications

Limited evidence exists for neurological conditions:

• Rett Syndrome: A systematic review examined mecasermin treatment, and a completed Phase 2 trial evaluated recombinant human IGF-1, but outcomes are not specified in available abstracts
• 22q13 Deletion Syndrome: A completed Phase 2 trial was conducted, but results are not detailed
• Autism Spectrum Disorders: Preliminary research suggests potential as both a diagnostic tool and treatment target, though this appears to be early-stage investigation

Other Applications

• Cardiovascular: A completed Phase 1/2 trial evaluated safety and efficacy in heart attack patients, but outcomes are not reported in available evidence
• Respiratory: A Phase 2 trial is recruiting to prevent bronchopulmonary dysplasia in extremely premature infants
• Retinopathy of Prematurity: A Cochrane review examined IGF-1 for prevention or treatment, but findings are not detailed

Evidence Limitations

The strength of evidence varies significantly by indication. While growth disorders have the most established evidence base with registry data, most other applications rely on single studies or ongoing trials. Specific quantitative outcomes, effect sizes, and statistical significance are not available from the provided abstracts, limiting the ability to assess clinical meaningfulness of reported benefits.

Disclaimer: This summary is for informational purposes only and should not replace professional medical advice. Consult healthcare providers for treatment decisions.